“The present findings reveal an imbalance in the expression and function of different elements of the endocannabinoid system in schizophrenia.
This outcome highlights the relevance of the endocannabinoid system in the pathophysiology of schizophrenia and emphasises its elements as potential targets in the search for new therapeutic strategies.”
https://www.ncbi.nlm.nih.gov/pubmed/31237179
https://journals.sagepub.com/doi/abs/10.1177/0269881119857205?journalCode=jopa
“Therapeutic potential of cannabinoids in schizophrenia.” https://www.ncbi.nlm.nih.gov/pubmed/24605939
“Cannabinoids for the Treatment of Schizophrenia: An Overview. Cannabinoids are found to be very useful in psychiatry because of their antipsychotic properties suggesting a therapeutic use. Cannabinoids treatments are both able to reduce the typical symptoms of schizophrenia and to slow down the disease aggravation.” https://www.ncbi.nlm.nih.gov/pubmed/26845552